🚨🗣️⬇️BREAKING: Members of @AmDiabetesAssn were escorted by police out of the convention center in New Orleans during the organization's annual meeting on Friday as they handed out copies of an editorial criticizing Trump administration changes to U.S. biomedical research.
Retatrutide, a triple receptor drug for GLP-1, GIP, and glucagon, is the most powerful weight loss drug yet. A significant issue is too much weight loss among the trial participants. New randomized trial results announced today with 28% body weight loss.
gift link https://t.co/82tRkOvQ49
New @Nature
A quintuple [GLP-1 + 4 other] receptor agonist drug that exceeds effects of the dual receptor (GLP-1 and GIP, tirzepatide) in the experimental model vs diabetes and obesity
(in case you thought a dual receptor was max effect, as also seen with retatrutide, a triple receptor agonist)
https://t.co/kqkNJ7My4B
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read the full review: https://t.co/SNdSrVXqWJ
In our latest preprint, we reveal that the ubiquitin ligase Cereblon (CRBN) acts as a critical regulator of SIM1 in the hypothalamus.
Check out our study on how this interaction drives central obesity: https://t.co/vsFUdWEd93
Researchers studied blood-based metabolome of over 23,000 individuals from 10 ethnically diverse cohorts. They identified 235 metabolites associated with future risk of T2D. By integrating genetic and modifiable lifestyle factors, their findings provide insights into T2D mechanisms and could improve risk prediction and inform precision prevention.
https://t.co/PnxC8YUgEW
The gastrointestinal side effects of GLP-1 drugs are mediated by the brain, not the gut. The gut-brain axis at work @jclinicalinvest
https://t.co/8meow41j83
The research groups of Hyung Jin Choi @ Seoul National University and Kevin Williams @ UT Southwestern found that DMH GLP-1R neurons mediate the feeling of fullness before actual eating.
dLS-GLP-1R neurons and the inhibitory pathway to LHA can regulate feeding behavior, which might serve as a potential therapeutic target for the treatment of eating disorders or #obesity@MolMetab https://t.co/cfkgCnhH6k